APA (7th ed.) Citation

TJ, S., S, K., MM, L., I, M., A, Z., E, L., . . . D, A. (2023). Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System. ORL; journal for oto-rhino-laryngology and its related specialties, 85(6), 329. https://doi.org/10.1159/000534545

Chicago Style (17th ed.) Citation

TJ, Stack, et al. "Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System." ORL; Journal for Oto-rhino-laryngology and Its Related Specialties 85, no. 6 (2023): 329. https://doi.org/10.1159/000534545.

MLA (9th ed.) Citation

TJ, Stack, et al. "Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System." ORL; Journal for Oto-rhino-laryngology and Its Related Specialties, vol. 85, no. 6, 2023, p. 329, https://doi.org/10.1159/000534545.